Literature DB >> 30536952

Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.

Cynthia L Gong1, Ann L Studdert1, Michaela Liedtke2.   

Abstract

Entities:  

Year:  2018        PMID： 30536952     DOI： 10.1002/ajh.25372

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

1.  Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.

Authors:  Xiaohui Zeng; Qiao Liu; Liubao Peng; Ye Peng; Lidan Yi; Xia Luo; Sini Li; Xiaomin Wan; Chongqing Tan
Journal:  Adv Ther       Date:  2021-03-26       Impact factor: 3.845

2.  Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).

Authors:  Ho Sup Lee; Kihyun Kim; Seok Jin Kim; Je-Jung Lee; Inho Kim; Jin Seok Kim; Hyeon-Seok Eom; Dok Hyun Yoon; Cheolwon Suh; Ho-Jin Shin; Yeung-Chul Mun; Min Kyoung Kim; Sung-Nam Lim; Chul Won Choi; Hye Jin Kang; Sung-Soo Yoon; Chang-Ki Min
Journal:  Am J Hematol       Date:  2020-01-24       Impact factor: 10.047

3.  Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma.

Authors:  Yaohua Cao; Lina Zhao; Tiantian Zhang; Weiling Cao
Journal:  Front Pharmacol       Date:  2021-03-01       Impact factor: 5.810

4.  Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.

Authors:  Michael Dolph; Gabriel Tremblay; Hoyee Leong
Journal:  Pharmacoeconomics       Date:  2021-08-09       Impact factor: 4.981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.